Navigation Links
Oxford BioMedica Announces Update from ARVO 2013

OXFORD, England, May 9, 2013 /PRNewswire/ --

-- UshStat® video selected to showcase theme of "Life-changing Research" --

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces an update from the 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Seattle, Washington (USA) on 5-9 May 2013.  The ARVO annual meeting is the largest gathering of eye and vision researchers in the world and this year's theme is "Life-changing Research".

Oxford BioMedica's collaborators at Oregon Health & Science University's Casey Eye Institute, Portland, Oregon submitted a video to ARVO which featured a patient who has been treated with UshStat®.  UshStat® is a novel gene-based treatment for Usher syndrome type 1B, the most common form of deaf-blindness, and was designed and developed by Oxford BioMedica using the Company's proprietary LentiVector® platform technology.

The video was awarded second place in a contest to promote the ARVO 2013 theme and was showcased at the Sunday 5 May, 2013 Keynote Session: click here to watch the video.

Oxford BioMedica also presented two posters entitled "Glaucoma-GT, a novel gene therapy treatment for primary open-angle glaucoma" (abstract ID: 2741 - A0185) and "The LentiVector® Gene Therapy Platform for Ocular Disease: a clinical update" (abstract ID: 2744 - A0188).

John Dawson , Chief Executive Officer of Oxford BioMedica, said: "Our ocular gene therapy programmes continue to receive recognition from the ARVO community and we thank our collaborators at OHSU's Casey Eye Institute for their support."

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and

2. Casey Eye Institute

The Casey Eye Institute at Oregon Health & Science University is a world-recognized academic eye center that attracts top specialists from around the globe.  As one of the leading institutions for vision research in the nation, Casey is known for developing and utilizing the very latest treatments and technologies.  From ground-breaking research and education, to specialty care in retina, glaucoma, inflammatory eye disease and refractive and plastic surgery - Casey's focus it to provide the best possible eye health in its clinics and in the community.  In addition, the Elks Children's Eye Clinic at Casey has been providing exceptional pediatric eye care since 1949, thanks to the generous support of the Oregon State Elks Association.  

3. LentiVector® gene delivery technology

Oxford BioMedica's LentiVector® gene delivery technology is one of the most advanced gene delivery systems currently available, which has many applications in product development and discovery research.  It is the system of choice for gene-based treatments addressing chronic and inherited diseases.  Oxford BioMedica has established a dominant intellectual property estate in the field of lentiviral-vector mediated gene delivery through its in-house research and from work conducted by the Company's co-founders at Oxford University.

4. Usher syndrome type 1B and UshStat®

Usher syndrome is the most common form of deaf-blindness which affects approximately 30,000-50,000 patients in the US and Europe.  One of the most common subtypes is Usher syndrome type 1B. The disease is caused by a mutation of the gene encoding myosin VIIA (MY07A), which leads to progressive retinitis pigmentosa combined with a congenital hearing defect.  UshStat® uses the Company's LentiVector® platform technology to deliver a corrected version of the MYO7A gene to address the vision loss associated with the disease.  On the basis of pre-clinical data, it is anticipated that a single application of UshStat® to the retina could provide long-term or potentially permanent stabilisation of vision.  There are currently no approved treatments available for Usher syndrome type 1B.

For further information, please contact:

Oxford BioMedica plc:
Lara Mott , Head of Corporate Communications
Tel: +44(0)1865-783-000

Casey Eye Institute:
Mirabai Vogt
Tel: +1-503-494-7986

Media Enquiries:
Mary Clark / Sarah Macleod / Claire Dickinson
Tel: +44(0)20-7920-2360

SOURCE Oxford BioMedica plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
2. Oxford Performance Materials and Biomet Microfixation Join Forces
3. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
4. Oxford Finance Completes $271.4 Million Securitization Transaction
5. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
6. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. Premier Biomedical CEO Interviewed by The Wall Street Transcript
9. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
10. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
11. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):